Physician

Elnaz Nassehzadeh Tabrizi

According to 2025 Medicare claims, Elnaz Tabrizi (NPI: 1376736553) practices rheumatology in the Charlotte-Concord-Gastonia, NC-SC market, with the plurality of this provider's patient population coming from Mecklenburg, NC. This provider's primary affiliated billing organization is ARTHRITIS AND OSTEOPOROSIS CONSULTANTS OF THE CAROLINAS PA (NPI: 1801843925; TIN: 562202409) and primary practice location at 28207-1108.

Tabrizi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 465 traditional Medicare patients, billed 97,814 HCPCS/CPT codes, and received $1,308,887 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,987 prescription claims across 296 beneficiaries totaling $1,681,212 in drug costs, led by Enbrel Sureclick (Etanercept). 2016 DME data shows 22 claims. Open Payments data shows 60 records totaling $1,260. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $201,179 to $1,308,887. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $357,230 and ending at $1,681,212. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	179	11,524	$201,179
2016	202	13,270	$328,815
2017	187	14,973	$375,500
2018	215	16,424	$540,803
2019	77	164	$11,881
2020	109	2,305	$49,946
2021	95	3,834	$64,445
2022	314	43,343	$722,797
2023	347	69,438	$1,054,763
2024	465	97,814	$1,308,887

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	207	1,661	$357,230
2016	254	2,051	$650,017
2017	243	1,629	$729,326
2018	249	1,582	$878,529
2019	122	507	$135,883
2020	133	799	$345,573
2021	150	1,046	$597,296
2022	213	1,073	$740,282
2023	267	1,669	$1,119,899
2024	296	1,987	$1,681,212

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	22	$1,398
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	199	358	$101
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	195	375	$92
96401	Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle	101	273	$56
77089	Calculation of trabecular bone score (tbs) using imaging data with interpretation and report on fracture risk	69	69	$25
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	151	265	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Enbrel Sureclick	Etanercept	56	1,568	$415,675
Orencia Clickject	Abatacept	33	924	$199,787
Humira(Cf) Pen	Adalimumab	19	532	$191,231
Cimzia (2 Pack)	Certolizumab Pegol	16	448	$98,371
Otezla	Apremilast	13	450	$72,982

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	60	$1,260	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Elnaz Nassehzadeh Tabrizi?

Tedicare shows public-source Medicare data for Elnaz Nassehzadeh Tabrizi (NPI 1376736553), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Elnaz Nassehzadeh Tabrizi have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Elnaz Nassehzadeh Tabrizi?

Elnaz Nassehzadeh Tabrizi is linked to ARTHRITIS AND OSTEOPOROSIS CONSULTANTS OF THE CAROLINAS PA (billing NPI 1801843925) in the available physician profile data.

Does Elnaz Nassehzadeh Tabrizi have Open Payments data?

Elnaz Nassehzadeh Tabrizi has 60 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.